About DNA Nanobots: DNA Nanobots is a platform biotech company with IP-based solutions for improved design and delivery of therapeutics including better targeting and larger payloads. The current focus is targeted non-viral gene delivery using DNA nanoparticle tech to fold up target gene(s) for stability and delivery. Nanobots are large, folded naked DNA nanoparticles that enable precision control over the number and spatial locations of targeting antibodies, drug payloads, antigens, and other components for oncology drugs and immunotherapies (cancer vaccines), as well as gene therapy.
DNA Nanobots offer major advantages over other delivery solutions, such as larger drug payloads than other Antibody-Drug Conjugates (ADCs) and better tissue targeting than lipid nanoparticles (LNPs). Nanobots are stable in vivo and not immunogenic (unless desired). We engineer Nanobots with precision to deliver drugs, antigens, siRNAs, mRNAs, genes, peptides, antibodies, biologics, small molecules, etc. to the right cell/tissue targets. We have good mouse study data showing excellent cancer vaccine responses and better tumor cell killing at lower doses of doxorubicin than free drug or ADC drugs. DNA Nanobots has a pipeline of its own therapeutic products but is focusing primarily on partnering with biopharma companies to help them improve performance of their therapeutics.
What we did: As the business founder and startup CEO, Jeff Spitzner identified the academic research lab in 2019, researched the technology and market potential for commercialization, helped them win grant funding in 2021, and began forming the company. I developed the business strategy, formed the company, then in-licensed the university technology in Feb. 2023. I raised non-dilutive capital and equity investments to hire the scientific founders, equip the lab, begin and run company operations, and win the first set of commercial customer projects. I successfully negotiated the license for additional gene delivery technology from UC Berkeley. Once DNA Nanobots was fully operational and ready for a dedicated CEO, the company hired an excellent full-time CEO and I moved to a strategic consulting position.